CINCINNATI , April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021 . Jack Kenny , Chief Executive Officer, and Bryan

CINCINNATI , April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Company’s

CINCINNATI , March 08, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for the

CINCINNATI , March 04, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference .

CINCINNATI , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S.

CINCINNATI , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S.

CINCINNATI , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S.

CINCINNATI , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) today announced financial results for the first quarter ended December 31, 2020 . First Quarter 2021 Highlights (Comparison to First Quarter Fiscal 2020): Consolidated net revenues of $92.9 million , up 96%

CINCINNATI , Feb. 03, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene ®

CINCINNATI , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has developed a series of innovative and high performing master mixes designed for